PE20231501A1 - Acidos pirazol piperidin carboxilicos sustituidos - Google Patents

Acidos pirazol piperidin carboxilicos sustituidos

Info

Publication number
PE20231501A1
PE20231501A1 PE2023001808A PE2023001808A PE20231501A1 PE 20231501 A1 PE20231501 A1 PE 20231501A1 PE 2023001808 A PE2023001808 A PE 2023001808A PE 2023001808 A PE2023001808 A PE 2023001808A PE 20231501 A1 PE20231501 A1 PE 20231501A1
Authority
PE
Peru
Prior art keywords
alkyl
increase
guanylate cyclase
soluble guanylate
pyrazole
Prior art date
Application number
PE2023001808A
Other languages
English (en)
Spanish (es)
Inventor
Alexandros Vakalopoulos
Marie-Pierre Collin-Kropelin
Hernandez Nuria Ortega
Andre Dieskau
Melissa Boultadakis-Arapinis
Lisa Candish
Timo Stellfeld
Ilka Mathar
Lucas Hudson Hofmeister
Peter Sandner
Frank Wunder
Lisa Dietz
Robert Alan Webster
Carsten Schmeck
Thomas Mondritzki
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of PE20231501A1 publication Critical patent/PE20231501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2023001808A 2020-12-10 2021-12-09 Acidos pirazol piperidin carboxilicos sustituidos PE20231501A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20213020 2020-12-10
PCT/EP2021/084987 WO2022122914A1 (en) 2020-12-10 2021-12-09 Substituted pyrazolo piperidine carboxylic acids

Publications (1)

Publication Number Publication Date
PE20231501A1 true PE20231501A1 (es) 2023-09-26

Family

ID=73793025

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001808A PE20231501A1 (es) 2020-12-10 2021-12-09 Acidos pirazol piperidin carboxilicos sustituidos

Country Status (30)

Country Link
US (1) US20240051935A1 (cg-RX-API-DMAC7.html)
EP (1) EP4259617B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023552583A (cg-RX-API-DMAC7.html)
KR (1) KR20230118144A (cg-RX-API-DMAC7.html)
CN (1) CN116710439B (cg-RX-API-DMAC7.html)
AR (1) AR124297A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021393988A1 (cg-RX-API-DMAC7.html)
CA (1) CA3204495A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001632A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023007335A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230242A (cg-RX-API-DMAC7.html)
DK (1) DK4259617T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000115A (cg-RX-API-DMAC7.html)
EC (1) ECSP23040828A (cg-RX-API-DMAC7.html)
ES (1) ES2997117T3 (cg-RX-API-DMAC7.html)
FI (1) FI4259617T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20247649B (cg-RX-API-DMAC7.html)
HR (1) HRP20241543T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069255T2 (cg-RX-API-DMAC7.html)
IL (1) IL303296A (cg-RX-API-DMAC7.html)
JO (1) JOP20230132A1 (cg-RX-API-DMAC7.html)
LT (1) LT4259617T (cg-RX-API-DMAC7.html)
MX (1) MX2023006903A (cg-RX-API-DMAC7.html)
PE (1) PE20231501A1 (cg-RX-API-DMAC7.html)
PL (1) PL4259617T3 (cg-RX-API-DMAC7.html)
PT (1) PT4259617T (cg-RX-API-DMAC7.html)
RS (1) RS66294B1 (cg-RX-API-DMAC7.html)
SA (1) SA523441083B1 (cg-RX-API-DMAC7.html)
SI (1) SI4259617T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022122914A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4011873A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
EP4011874A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
CN119300815A (zh) 2022-06-09 2025-01-10 拜耳公司 用于治疗女性射血分数保留型心力衰竭的可溶性鸟苷酸环化酶激活剂
JP2026504406A (ja) * 2023-01-31 2026-02-05 インビボサイエンシーズ インコーポレイテッド 駆出率保持型心不全(HFpEF)の治療に関するシステムおよび方法
AU2024348074A1 (en) * 2023-09-27 2026-04-30 Haisco Pharmaceutical Group Co., Ltd. Pyrazole carboxylic acid derivative and use thereof in medicine
TW202535380A (zh) * 2024-01-30 2025-09-16 大陸商海思科醫藥集團股份有限公司 吡唑羧酸衍生物及其在醫藥上的應用
WO2026145681A1 (zh) * 2025-01-03 2026-07-09 上海齐鲁制药研究中心有限公司 杂环羧酸类衍生物、其制备方法及其在医药上的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
CN101939053A (zh) * 2007-09-06 2011-01-05 默沙东公司 可溶性的鸟苷酸环化酶活化剂
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
ES2635340T3 (es) 2010-02-27 2017-10-03 Bayer Intellectual Property Gmbh Ariltriazolonas ligadas a bis-arilo y su uso
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2590979A1 (de) 2010-07-09 2013-05-15 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
WO2012058132A1 (en) 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
MX338887B (es) * 2012-09-07 2016-05-04 Boehringer Ingelheim Int Alcoxipirazoles como activadores de guanilato ciclasa soluble.
WO2015095515A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma
US20170313665A1 (en) 2014-11-03 2017-11-02 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
CA3204595A1 (en) * 2020-12-10 2022-06-16 Bayer Aktiengesellschaft Substituted pyrazolyl piperidine carboxylic acids
WO2022122917A1 (en) * 2020-12-10 2022-06-16 Bayer Aktiengesellschaft The use of sgc activators for the treatment of ophthalmologic diseases

Also Published As

Publication number Publication date
US20240051935A1 (en) 2024-02-15
IL303296A (en) 2023-07-01
AU2021393988A9 (en) 2024-09-19
SA523441083B1 (ar) 2025-06-12
CN116710439A (zh) 2023-09-05
CO2023007335A2 (es) 2023-06-09
ECSP23040828A (es) 2023-07-31
AR124297A1 (es) 2023-03-15
FI4259617T3 (fi) 2024-11-27
JP2023552583A (ja) 2023-12-18
DOP2023000115A (es) 2023-07-16
LT4259617T (lt) 2024-12-10
EP4259617A1 (en) 2023-10-18
CA3204495A1 (en) 2022-06-16
GEAP202316287A (en) 2023-09-11
CL2023001632A1 (es) 2023-11-10
HRP20241543T1 (hr) 2025-01-03
ES2997117T3 (en) 2025-02-14
GEP20247649B (en) 2024-07-25
MX2023006903A (es) 2023-06-26
CN116710439B (zh) 2026-05-26
RS66294B1 (sr) 2025-01-31
KR20230118144A (ko) 2023-08-10
EP4259617B1 (en) 2024-10-23
TW202237589A (zh) 2022-10-01
PT4259617T (pt) 2024-12-05
WO2022122914A1 (en) 2022-06-16
SI4259617T1 (sl) 2025-02-28
JOP20230132A1 (ar) 2023-06-08
PL4259617T3 (pl) 2025-03-17
HUE069255T2 (hu) 2025-02-28
DK4259617T3 (da) 2024-12-09
CR20230242A (es) 2023-07-19
AU2021393988A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
PE20231502A1 (es) Acidos pirazolo piperidin carboxilicos sustituidos
AR124297A1 (es) Ácidos pirazol piperidin carboxílicos sustituidos
Taylor et al. Comparative clinical study of pulsatile and non-pulsatile perfusion in 350 consecutive patients.
Antoniou et al. Inhaled nitric oxide plus iloprost in the setting of post-left assist device right heart dysfunction
JP2021516240A5 (cg-RX-API-DMAC7.html)
Jansen et al. Reduction in prime volume attenuates the hyperdynamic response after cardiopulmonary bypass
RU2012120749A (ru) Производное 5-гидроксипиримидин-4-карбоксамида
Prathanee et al. Custodial-HTK solution for myocardial protection in CABG patients
CZ286825B6 (en) Substituted cyclohexane derivatives and medicament in which the derivatives are comprised
RU2014151360A (ru) Производные пиразола и их применение в качестве lpar5 антагонистов
RU163089U1 (ru) Устройство контура доставки газо-воздушной смеси для аппаратов искусственного кровообращения
RU2675552C1 (ru) Способ анестезиологического обеспечения операций на сердце с искусственным кровообращением у пациентов с вторичной высокой легочной гипертензией
Umeki et al. Analysis of systemic vascular resistance after cardiac surgery: a retrospective cohort study
JP4491866B2 (ja) アシルスルホンアミド誘導体
Shinohara et al. Ischemic postconditioning promotes left ventricular functional recovery after cardioplegic arrest in an in vivo piglet model of global ischemia reperfusion injury on cardiopulmonary bypass
Ascenzi et al. Update on complications of pediatric cardiac surgery
WO2013099048A1 (ja) ジフェニルメチルピペラジン誘導体、及びそれを用いた医薬組成物
Bayram et al. ECMO Use in Postcardiotomy Syndrome: A Single Center Experince
Ela et al. Advantages of autologous blood transfusion in off-pump coronary artery bypass
Marichev et al. The Effect of Nitric Oxide Supplied to the Sweep Gas of the Oxygenator on the Formation of Gaseous Microemboli during Cardiopulmonary Bypass (Experimental Study)
Foroughi et al. Cardiovascular complications and management after cardiac surgery
Georgiou et al. Priming solutions for cardiopulmonary bypass circuits
Schmid et al. Can goal-directed hemodynamic management improve renal outcome after major non-cardiac surgery?: 4AP3-2
Bettex et al. Inaccuracy of cardiac output determination by transoesophageal echocardiography: 125
Baker Viscosity and perfusion